Quipt Home Medical (QIPT) Q4 2024 earnings summary

Executive summary

• Fiscal 2024 revenue reached $245.9 million, up 16.2% year-over-year, with adjusted EBITDA of $57.9 million (23.5% margin), and recurring revenue comprising 78% of total.

• Sequential organic growth returned positive at 1% in Q4 2024, with year-over-year organic growth at 3%.

• Customer base grew to 314,000 unique patients, with total setups/deliveries up 13% and resupply setups/deliveries up 21%.

• Focused on respiratory care (80% of product mix), leveraging demographic trends and expanding nationwide reach.

• Management anticipates a return to historical organic growth in 2025, supported by scalable operations and favorable demographics.

Financial highlights

• Fiscal 2024 recurring revenue was $190.8 million (78% of total), driven by the resupply platform.

• Adjusted EBITDA: $57.9 million (23.5% margin), up from $50.6 million in 2023; Q4 2024 adjusted EBITDA: $13.4 million (21.8% margin), down 8.8% year-over-year.

• Cash flow from operations: $35.7 million for fiscal 2024, compared to $37 million in 2023.

• Net leverage ratio at 1.6x adjusted EBITDA, reflecting conservative debt management.

• Transition from IFRS to U.S. GAAP reduced 2023 revenue by $10.1 million, with no impact on adjusted EBITDA or net loss.

Outlook and guidance

• Expecting a return to historical organic growth rates (8%-10%) in calendar 2025 as headwinds subside.

• Guidance for fiscal 2025: 6%-8% free cash flow as a percentage of revenue.

• Positive CPI adjustments for 2025 fee schedules (2.4%-3%) to support organic growth.

• Focus remains on expanding recurring revenue, leveraging technology, and disciplined inorganic growth.